The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2019

Filed:

Aug. 01, 2010
Applicants:

Ada Maria DE Barcelos Alves, Rio de Janeiro, BR;

Adriana DE Souza Azevedo, Niteroi, BR;

Ricardo Galler, Rio de Janeiro, BR;

Marcos Da Silva Freire, Rio de Janeiro, BR;

Inventors:

Ada Maria de Barcelos Alves, Rio de Janeiro, BR;

Adriana de Souza Azevedo, Niteroi, BR;

Ricardo Galler, Rio de Janeiro, BR;

Marcos da Silva Freire, Rio de Janeiro, BR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/53 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01);
Abstract

The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.


Find Patent Forward Citations

Loading…